Read + Share
Amedeo Smart
Independent Medical Education
Danilov AV, Persky DO. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. Br J Haematol 2021;193:15-25.PMID: 33216986
Email
LinkedIn
Facebook
Twitter
Privacy Policy